Close menu




March 7th, 2022 | 13:05 CET

Valneva, Defence Therapeutics, MorphoSys - Blockbuster potential

  • Biotechnology
Photo credits: pixabay.com

Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.

time to read: 4 minutes | Author: Armin Schulz
ISIN: VALNEVA SE EO -_15 | FR0004056851 , DEFENCE THERAPEUTICS INC | CA24463V1013 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:


    Valneva - Waiting for EU approval

    For Valneva, hopes for a blockbuster rest on the Corona vaccine VLA2001. While other companies have already achieved large sales, the French biotech company Valneva is late to the game. The advantage the Company has is in the nature of the vaccine. After Bahrain granted emergency approval on March 1, Thomas Lingelbach, chief executive officer of Valneva, said, "As the only double-adjuvanted, inactivated COVID-19 vaccine approved in Bahrain, VLA2001 will provide the Bahraini population and medical community with a differentiated vaccine option."

    Unlike its competitors, Valneva offers a dead vaccine. Even though the active ingredient Novavax is titled the same, it is still protein-based only. With 1 million doses of VLA2001 sold in Bahrain, a blockbuster has not yet been created. Approval of the vaccine in Europe and the United Kingdom could bring the Company significantly closer to this goal. In Europe, the Company is hoping for approval this month. To this end, the questions recently sent to the Company by the EMA must now be answered.

    If these answers are sufficient, the approval will likely be granted soon. The Company could then sell 27 million doses in 2022. It is still unclear how well the vaccine can be sold. Inevitable vaccination fatigue has set in, and demand for Novavax is falling short of expectations. The stock market, which pushed the stock up to EUR 16.20 following the Bahrain announcement, appears skeptical. At the moment, the share is trading at just EUR 13.80. Good news, such as the Lyme disease vaccine developed in cooperation with Pfizer, is currently falling flat in the challenging market environment.

    Defence Therapeutics - Looking for suitable cooperations

    The Canadian biotech company Defence Therapeutics is also working on a corona vaccine. It is administered nasally and has been successfully tested on animals. The Company has two business areas. One is the fight against infectious diseases such as Corona or HPV infections. The other is the immuno-oncology division, focusing primarily on breast and skin cancer. Both areas draw on the patented Accum biological drug booster platform. This makes it possible to use the active ingredients in a targeted manner, which multiplies the effect.

    The advantage is that the Company does not have to manufacture the antibody-drug conjugates (ADCs) itself. The manufacturers of ADCs can benefit from Accum's technology, and even failed compounds that have had problems with dosing may still be able to become successful. Dr. Moutih Rafei, director and VP of research and development at Defence Therapeutics, confirmed this in a recent interview. The Company is currently preparing for Phase 1 clinical trials of AccuTOX against skin and breast cancer. Tests have shown that the drug can fight 9 different tumors. To accelerate the process, on February 16, the Company announced a collaboration with CATO SMS, which has over 30 years of experience in clinical trials.

    In parallel, the Company is trying to find suitable partners with whom it can jointly develop special preparations. Since tests repeatedly show that the Accum platform works successfully in various application areas, cooperation should only be a matter of time. Especially since the growth prospects in the markets where the Company is currently active are excellent. For a deeper insight, check out the analysis from researchanalyst.com. On February 14, the stock closed the price gap from May 2021, providing the low for the year at 3.20 Canadian dollars (CAD). Currently, the stock is trading at CAD 4 and moving sideways. Should cooperations be announced, the share has some upside potential. The high in 2021 was CAD 8.15.

    MorphoSys - Continues to fall

    The former German biotech highflyer MorphoSys is now only a shadow of its former self. The reason is a restructuring of the business from a contract research organization to a pharmaceutical company. The Company's founder decided to leave the Company when this idea was more challenging to implement than expected. The acquisition of Constellation Pharmaceuticals for EUR 1.5 billion had an even worse effect. To raise the financing, the Company gave away its silverware. A large part of the licensing income no longer belongs to the Company.

    Instead, it owns Constellation's two product candidates: pelabresib and CPI-0209. Pelabresib is in phase 3 clinical trials and combats myelofibrosis. CPI-0209 is in Phase 2 clinical trials and is intended to target advanced tumors. If it succeeds in reaching market maturity, the investment in Constellation could pay off in the end. The Company has another candidate, tafasitamab, in phase 3 trials. Its current flagship cancer drug Monjuvi is lagging behind big expectations. In 2022, sales for the drug are expected to climb to USD 110-135 million.

    Due to the high costs in phase 3 trials, 2022 will also be challenging. This gloomy outlook is also reflected in the share price, which has formed a flawless downward trend. Those who speculated on a countermovement have so far been regularly disappointed. The share is currently trading at EUR 22.20. Market capitalization is now only around EUR 760 million. That is just half of what was paid for the takeover. The Company itself has now become a takeover target.


    All three companies have the opportunity to produce a blockbuster. Valneva, which already has purchase agreements in its pocket, is the furthest along. Defence Therapeutics is very variably positioned through its Accum platform and can cooperate with many large companies. MorphoSys needs successful phase 3 studies to achieve the turnaround.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read

    Commented by Stefan Feulner on February 1st, 2023 | 20:29 CET

    BioNTech, Defence Therapeutics, PAION - All dams broken

    • Biotechnology

    High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read